Platelet Aggregation Inhibitors
"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
| Descriptor ID |
D010975
|
| MeSH Number(s) |
D27.505.954.502.780
|
| Concept/Terms |
Platelet Aggregation Inhibitors- Platelet Aggregation Inhibitors
- Aggregation Inhibitors, Platelet
- Inhibitors, Platelet Aggregation
- Blood Platelet Antiaggregants
- Antiaggregants, Blood Platelet
- Platelet Antiaggregants
- Antiaggregants, Platelet
- Blood Platelet Aggregation Inhibitors
Antiplatelet Agents- Antiplatelet Agents
- Agents, Antiplatelet
- Antiplatelet Drugs
- Drugs, Antiplatelet
Platelet Antagonists- Platelet Antagonists
- Antagonists, Platelet
- Blood Platelet Antagonists
- Antagonists, Blood Platelet
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".
This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2001 | 1 | 2 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 4 | 4 |
| 2011 | 1 | 2 | 3 |
| 2012 | 4 | 2 | 6 |
| 2013 | 5 | 2 | 7 |
| 2014 | 4 | 1 | 5 |
| 2015 | 3 | 4 | 7 |
| 2016 | 13 | 6 | 19 |
| 2017 | 11 | 4 | 15 |
| 2018 | 4 | 6 | 10 |
| 2019 | 10 | 4 | 14 |
| 2020 | 10 | 8 | 18 |
| 2021 | 2 | 11 | 13 |
| 2022 | 3 | 6 | 9 |
| 2023 | 2 | 10 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.
-
Reply: Decoding Ticagrelor Dyspnea: Central Apnea Screening Before Drug Discontinuation. JACC Cardiovasc Interv. 2024 Feb 12; 17(3):452-453.
-
Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(3):425-434.
-
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
-
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2023 10 23; 16(20):2514-2524.
-
Effect of chronic antiplatelet therapy on clinical outcomes of endovascular thrombectomy for treatment of acute ischemic stroke. Neurosurg Focus. 2023 Oct; 55(4):E20.
-
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. Eur Heart J Acute Cardiovasc Care. 2023 Sep 25; 12(9):594-603.
-
Bleeding and Ischemic Risks of Ticagrelor?Monotherapy After Coronary?Interventions. J Am Coll Cardiol. 2023 08 22; 82(8):687-700.
-
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. Circulation. 2023 06 20; 147(25):1933-1944.
-
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial. Eur Heart J Cardiovasc Pharmacother. 2023 06 02; 9(4):328-336.
-
Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry. Am Heart J. 2023 09; 263:26-34.